Daily Sepsis Research Analysis
Rapid antimicrobial resistance diagnostics and evidence-based therapy choices dominate today’s sepsis literature. A novel, ultra-low-cost phenotypic test enables carbapenemase typing directly from positive blood cultures within 1.5–2 hours, while a decision-analytic model projects mortality and cost benefits of molecular AMR diagnostics in resource-limited settings. A meta-analysis supports cefazolin as a non-inferior and safer option vs antistaphylococcal penicillins for MSSA bacteraemia.
Summary
Rapid antimicrobial resistance diagnostics and evidence-based therapy choices dominate today’s sepsis literature. A novel, ultra-low-cost phenotypic test enables carbapenemase typing directly from positive blood cultures within 1.5–2 hours, while a decision-analytic model projects mortality and cost benefits of molecular AMR diagnostics in resource-limited settings. A meta-analysis supports cefazolin as a non-inferior and safer option vs antistaphylococcal penicillins for MSSA bacteraemia.
Research Themes
- Rapid, low-cost carbapenemase detection directly from positive blood cultures
- Health economic impact of molecular AMR diagnostics for sepsis in resource-limited settings
- Evidence synthesis guiding first-line therapy for MSSA bacteraemia
Selected Articles
1. REL/DPA/AVI method: a novel approach for rapid detection of carbapenemase-producing Enterobacterales directly from positive blood cultures based on optical density.
The REL/DPA/AVI phenotypic test identified Class A, B, and D carbapenemases directly from positive blood cultures in 1.5–2 hours using optical density readouts. Sensitivity at 1.5 hours reached 97.6% (Class A) and 100% (Class B), with Class D improving to 85.7% at 2 hours. The method compares favorably with mCIM/eCIM and APB-EDTA and costs under $1 USD per test.
Impact: Rapid, accurate, and ultra-low-cost carbapenemase typing could enable earlier effective therapy for CRE bloodstream infections and be scalable in low-resource settings.
Clinical Implications: Hospitals can adopt a rapid phenotypic workflow to guide early targeted therapy for CRE bacteraemia, potentially reducing time on inappropriate antibiotics and improving outcomes, especially where molecular tests are unaffordable.
Key Findings
- REL/DPA/AVI delivered results within 1.5–2 hours from blood culture positivity using OD measurements.
- Sensitivity at 1.5 hours: Class A 97.56% (40/41), Class B 100% (82/82), Class D 71.43% (5/7); Class D improved to 85.71% (6/7) at 2 hours.
- Per-test consumable cost is under $1 USD, offering a substantial economic advantage over existing methods.
Methodological Strengths
- Head-to-head comparison with standard phenotypic methods (mCIM/eCIM, APB-EDTA).
- Clear time-resolved sensitivity reporting and defined inhibitor combinations targeting Classes A/B/D.
Limitations
- Validation used contrived (seeded) blood cultures; prospective performance in clinical patient samples was not assessed.
- Early sensitivity for Class D carbapenemases was lower; specificity and workflow impact were not fully detailed.
Future Directions: Prospective clinical validation on consecutive positive blood cultures, assessment of specificity and mixed-mechanism strains, and implementation studies measuring time-to-effective therapy and patient outcomes.
UNLABELLED: The high mortality rate associated with carbapenem-resistant Enterobacterales (CRE), particularly for bloodstream infections (BSI), underscores the urgent need for early identification and differentiation of its resistance mechanisms. In China, traditional phenotypic detection methods for carbapenemases, including the modified Carbapenem Inactivation Method (mCIM), EDTA Carbapenemase Inactivation Method (eCIM), and the carbapenemase inhibitor 3-aminophenylboronic acid (APB) and EDTA enhancement method (APB-EDTA method), are widely used; however, they are time cons
2. Modeling the impact and cost of a culture-dependent molecular test for antimicrobial resistance in resource-limited settings.
A decision-analytic model suggests that implementing culture-dependent molecular AMR diagnostics can reduce deaths by up to 6%, hospital days by 5%, and inappropriate antibiotic days by 21% when diagnostic coverage is high and culture turnaround is rapid. Cost neutrality per test was projected around $109 in India to $585 in South Africa; implementation at $100 could generate system savings.
Impact: Provides quantitative, context-specific thresholds for when molecular AMR diagnostics improve outcomes and remain cost neutral, directly informing policy and implementation in high-AMR, resource-limited hospitals.
Clinical Implications: Health systems should prioritize high diagnostic coverage and faster culture turnaround when implementing molecular AMR tests for bloodstream infections to maximize mortality and cost benefits.
Key Findings
- With 100% coverage, faster culture turnaround, and high AMR prevalence, the model projected up to 6% fewer deaths, 5% fewer hospital days, and 21% fewer days on inappropriate antibiotics.
- Cost neutrality thresholds per molecular test ranged from ~$109 (India) to ~$585 (South Africa) across scenarios.
- Impact is constrained by delayed culture turnaround and by effective empiric therapy; coverage is a major driver of benefit.
Methodological Strengths
- Scenario-based modeling across multiple health system parameters with clear outcome and cost endpoints.
- Explicit threshold and sensitivity analyses enabling policy translation.
Limitations
- Model outcomes depend on assumptions and local parameter accuracy; not validated by prospective clinical implementation.
- Requires functional blood culture infrastructure; benefits diminish with slow turnaround or highly effective empiric regimens.
Future Directions: Prospective implementation studies in diverse hospitals to validate predicted mortality and cost outcomes, evaluate antibiotic stewardship impact, and refine local parameterization.
BACKGROUND: Limited diagnostic access in resource-limited settings contributes to poor health outcomes among bacterial sepsis patients and the spread of antimicrobial resistance (AMR). Molecular diagnostic profiling of AMR may enable faster targeting of antibiotic therapies, improving clinical outcomes, reducing AMR development, and saving costs. METHODS: We modeled the impact of a culture-dependent molecular diagnostic for pathogen identification and resistance testing among hospitalized bloodstream in
3. Cefazolin vs. antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis.
Across 30 observational studies (n≈15,513), cefazolin was non-inferior for 30-day mortality versus antistaphylococcal penicillins, with an overall OR 0.73 (95% CI 0.62–0.85). Benefits were consistent across flucloxacillin, nafcillin, cloxacillin, and oxacillin comparisons, and safety favored cefazolin (lower nephrotoxicity and discontinuation).
Impact: Clarifies first-line therapy for MSSA bacteraemia, a common cause of sepsis, with potential to reduce toxicity without compromising effectiveness.
Clinical Implications: Cefazolin can be considered a first-line agent for MSSA bacteraemia, including severe presentations, given comparable or improved mortality and better safety compared with antistaphylococcal penicillins.
Key Findings
- Cefazolin reduced 30-day mortality odds versus antistaphylococcal penicillins (OR 0.73, 95% CI 0.62–0.85), meeting prespecified non-inferiority.
- Consistent effects across individual comparators: e.g., vs flucloxacillin OR 0.92 (95% CI 0.73–1.16); vs nafcillin OR 0.58 (95% CI 0.28–1.17).
- Safety favored cefazolin with lower nephrotoxicity and discontinuation rates across most comparisons.
Methodological Strengths
- Large pooled sample with stratified analyses by individual antistaphylococcal penicillins.
- Pre-specified non-inferiority margin and evaluation of multiple safety endpoints.
Limitations
- All data from observational studies with moderate to high risk of bias; no randomized trials available.
- Primary mortality analysis used unadjusted pooled OR; residual confounding (e.g., source control, inoculum effect) likely.
Future Directions: Await results of ongoing RCTs comparing cefazolin to (flu)cloxacillin; examine endocarditis and high-inoculum subgroups and the impact of blaZ/inoculum effects.
BACKGROUND: There is debate on whether cefazolin or antistaphylococcal penicillins should be the first-line treatment for methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia. Ongoing trials are investigating whether cefazolin is non-inferior to (flu)cloxacillin, but it remains uncertain whether these findings apply to other antistaphylococcal penicillins. OBJECTIVES: We conducted a systematic review and meta-analysis comparing cefazolin with each of the individual antistaphylococcal peni